Nexgel names Brian Kieser interim CEO, replacing Adam Levy
NXGL•Strategic review and board oversight
A special board committee for the strategic review, chaired by Kevin Harris with Steve Glassman, will oversee restructuring and liquidity and capital structure matters.
Interim CEO appointment and leadership change
Nexgel named Brian Kieser interim CEO effective Aug. 21, 2026, amid an operational integration push and a broader strategic review.
Kieser previously worked on integrating the BioNX Surgical division, manufacturing transition, commercialization, financing and strategic planning via the Sequence Life Science partnership.
Adam Levy will step down as CEO and leave the company effective Aug. 21, 2026. Levy will provide transition assistance for 90 days focused on knowledge transfer, key relationships, BioNX Surgical integration and public reporting support.
